Abstract: A method and system for generating a patient specific anatomical heart model is disclosed. Volumetric image data, such as computed tomography (CT), echocardiography, or magnetic resonance (MR) image data of a patient's cardiac region is received. Individual models for multiple heart components, such as the left ventricle (LV) endocardium, LV epicardium, right ventricle (RV), left atrium (LA), right atrium (RA), mitral valve, aortic valve, aorta, and pulmonary trunk, are estimated in said volumetric cardiac image data. A multi-component patient specific anatomical heart model is generated by integrating the individual models for each of the heart components. Fluid Structure Interaction (FSI) simulations are performed on the patient specific anatomical model, and patient specific clinical parameters are extracted based on the patient specific heart model and the FSI simulations. Disease progression modeling and risk stratification are performed based on the patient specific clinical parameters.

Abstract: IGF1R biomarkers useful in a method for identifying and monitoring a mammal that will respond therapeutically to a method of treating cancer comprising administering an IGF1R modulator, wherein the method comprises (a) exposing the mammal to the IGF1R modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the IGF1R modulator indicates that the mammal will respond therapeutically to the method of treating cancer and (c) wherein the level of the biomarker in a mammal after exposure to a IGF1R modulator indicates that the mammal has responded therapeutically to the method of treating cancer.

Abstract: Methods and systems for identifying a primer pair for polymerase chain reaction specific to one or more target genomes. Methods and systems of the present disclosure can be used to identify primers that can distinguish between target genomes and closely related non-target genomes.

Abstract: The present invention provides methods useful for predicting the likelihood that a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, and diagnostic methods and kits thereof.

Abstract: A method and system for generating a patient specific anatomical heart model is disclosed. Volumetric image data, such as computed tomography (CT), echocardiography, or magnetic resonance (MR) image data of a patient's cardiac region is received. Individual models for multiple heart components, such as the left ventricle (LV) endocardium, LV epicardium, right ventricle (RV), left atrium (LA), right atrium (RA), mitral valve, aortic valve, aorta, and pulmonary trunk, are estimated in said volumetric cardiac image data. A multi-component patient specific anatomical heart model is generated by integrating the individual models for each of the heart components. Fluid Structure Interaction (FSI) simulations are performed on the patient specific anatomical model, and patient specific clinical parameters are extracted based on the patient specific heart model and the FSI simulations. Disease progression modeling and risk stratification are performed based on the patient specific clinical parameters.

Abstract: Methods and systems for identifying a primer pair for polymerase chain reaction specific to one or more target genomes. Methods and systems of the present disclosure can be used to identify primers that can distinguish between target genomes and closely related non-target genomes.

Abstract: IGF1R biomarkers useful in a method for identifying and monitoring a mammal that will respond therapeutically to a method of treating cancer comprising administering an IGF1R modulator, wherein the method comprises (a) exposing the mammal to the IGF1R modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the IGF1R modulator indicates that the mammal will respond therapeutically to the method of treating cancer and (c) wherein the level of the biomarker in a mammal after exposure to a IGF1R modulator indicates that the mammal has responded therapeutically to the method of treating cancer.